NFE2L2 and neoplasm: Therefore, it may be pertinent to stratify patients for whether this strategy poses more benefits that outweigh potential harms whereby if the patient presents with an NRF2-overexpressed tumour and clinicians are to prescribe, e.g., doxorubicin, an NRF2 activator may be a useful strategy to limit the cardiotoxic risk as no further benefit will be afforded to the neoplasm.